| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.03. | Cologuard campaign reunites 'Full House' stars to give 'The Talk' about colon cancer screening | ||
| 24.03. | Karyopharm, looking to jump start Expovio, reports mixed results in myelofibrosis | ||
| 24.03. | Lilly to remove certain insulin products from European markets by 2027 | ||
| 24.03. | Wilmington PharmaTech commits $50M to US API expansion | ||
| 24.03. | WuXi Bio's record number of new projects in 2025 leaned heavily on US clients | ||
| 24.03. | Gilead inks Manta pact to dive deeper into cancer patient support | ||
| 24.03. | Strides recalls nearly 90K bottles of children's ibuprofen after contamination complaints | ||
| 23.03. | Gilead CEO Dan O'Day nets $28.4M pay package as security and travel costs top $2M | ||
| 23.03. | Insmed sets up Arikayce for a significant label expansion on new ph. 3 data | ||
| 23.03. | EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race | ||
| 23.03. | FDA mandates label updates to common Parkinson's meds based on seizure risk finding | ||
| 23.03. | Novartis joins Lilly, AstraZeneca in China expansion with $480M commitment to boost manufacturing, R&D | ||
| 23.03. | Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant | ||
| 23.03. | FDA solicits feedback on controversial national priority voucher review pathway | ||
| 20.03. | Sanofi backs 2 more documentary films about rare blood disorders | ||
| 20.03. | With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics | ||
| 20.03. | ACIP member's miscommunication on vaccine panel's future adds to confusion after court ruling | ||
| 20.03. | Rhythm's Imcivree scores 'transformative' FDA approval in brain-damage related obesity | ||
| 19.03. | CSL warns of supply shortfall, treatment delays for hemophilia gene therapy Hemgenix | ||
| 19.03. | Novo's Wegovy HD passes muster under FDA national priority voucher program | ||
| 19.03. | Maryland bill calls for more transparency in pharma's disease awareness campaigns | ||
| 19.03. | Collegium ponies up $650M to gain ADHD drug Azstarys from Corium | ||
| 19.03. | After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease | ||
| 19.03. | AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai | ||
| 19.03. | CDMO Axplora to pump $60M into Italian complex API plant |